Gram-negative bacterial surface antigens and endogenous anti-alpha-gal antibodies (Alpha-gal/GNB antigen complex)

This target system involves the recruitment of naturally occurring human antibodies to the surface of pathogenic Gram-negative bacteria. Humans, unlike most other mammals, lack the enzyme alpha-1,3-galactosyltransferase and consequently produce high levels of endogenous antibodies (anti-Gal) against the alpha-gal (Galalpha1-3Galbeta1-4GlcNAc-R) carbohydrate epitope (Macher & Galili, 2008). Therapeutic strategies, such as Alphamers, utilize bifunctional molecules—typically an aptamer or small molecule linked to alpha-gal—to bridge bacterial surface antigens and these circulating anti-Gal antibodies (Centauri Therapeutics, 2024). Once the alpha-gal epitope is displayed on the bacterial surface, it triggers the classical complement pathway and enhances opsonization, leading to rapid bacterial clearance by the innate immune system (Galili, 2013). This mechanism is particularly relevant for treating multi-drug resistant (MDR) infections, such as those caused by Pseudomonas aeruginosa or Klebsiella pneumoniae, by leveraging the host's pre-existing immunity. The approach is designed to bypass traditional antibiotic resistance mechanisms by utilizing the host's own immune effector functions.

Other names

Alpha-gal epitopeAnti-Gal antibodiesGalalpha1-3Galbeta1-4GlcNAc-RAlphamer targetαGal

Recruitment of endogenous anti-alpha-gal antibodies to the bacterial surface via bifunctional molecules to induce complement-mediated lysis and opsonophagocytosis.